Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Afd Pharmacoepi & Clinical Pharmacology"'
Autor:
Bruin, Frans de, Hek, Karin, Lieshout, Jan van, Verduijn, Monique, Langendijk, Pim, Bouvy, Marcel, Teichert, Martina, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Journal of Oncology Pharmacy Practice, 25(7), 1613. SAGE Publications Ltd
Journal of Oncology Pharmacy Practice, 25, 7, pp. 1613-1621
Journal of Oncology Pharmacy Practice, 25(7), 1613-1621
Journal of Oncology Pharmacy Practice
Journal of Oncology Pharmacy Practice, 25, 1613-1621
Journal of Oncology Pharmacy Practice, 25, 7, pp. 1613-1621
Journal of Oncology Pharmacy Practice, 25(7), 1613-1621
Journal of Oncology Pharmacy Practice
Journal of Oncology Pharmacy Practice, 25, 1613-1621
IntroductionOpioid-induced constipation is a clinically relevant side effect and a cause of potentially avoidable drug-related hospital admissions.ObjectivesTo describe the presence of laxative co-medication, the reasons for not starting laxatives an
Autor:
Schuller, Yvonne, Gispen-de Wied, Christine, Hollak, Carla E M, Leufkens, Hubertus G M, Stoyanova-Beninska, Violeta, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Journal of Clinical Pharmacology
Journal of clinical pharmacology, 59(2), 229-244. Wiley-Blackwell
Journal of Clinical Pharmacology, 59(2), 229. SAGE Publications Inc.
Journal of clinical pharmacology, 59(2), 229-244. Wiley-Blackwell
Journal of Clinical Pharmacology, 59(2), 229. SAGE Publications Inc.
In the development process for new drugs, dose‐finding studies are of major importance. Absence of these studies may lead to failed phase 3 trials and delayed marketing authorization. In our study we investigated to what extent dose‐finding studi
Autor:
Abdullah-Koolmees, Heshu, van Keulen, Antonius M., Nijenhuis, Marga, Deneer, Vera H.M., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2021)
Frontiers in Pharmacology, 11, 1. Frontiers Media S.A.
Frontiers in pharmacology
Frontiers in Pharmacology
Frontiers in Pharmacology, 11, 1. Frontiers Media S.A.
Frontiers in pharmacology
Frontiers in Pharmacology
Many studies have shown that the efficacy and risk of side effects of drug treatment is influenced by genetic variants. Evidence based guidelines are essential for implementing pharmacogenetic knowledge in daily clinical practice to optimize pharmaco
Autor:
Favié, Laurent M A, de Haan, Timo R, Bijleveld, Yuma A, Rademaker, Carin M A, Egberts, Toine C G, Nuytemans, Debbie H G M, Mathôt, Ron A A, Groenendaal, Floris, Huitema, Alwin D R, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Clinical Pharmacology and Therapeutics, 108(5), 1098. Nature Publishing Group
Clinical Pharmacology and Therapeutics
Clinical pharmacology and therapeutics, 108(5), 1098-1106. Wiley-Blackwell
Clinical Pharmacology and Therapeutics
Clinical pharmacology and therapeutics, 108(5), 1098-1106. Wiley-Blackwell
Drug dosing in encephalopathic neonates treated with therapeutic hypothermia is challenging; exposure is dependent on body size and maturation but can also be influenced by factors related to disease and treatment. A better understanding of underlyin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8192d8e0e878da7b237b91cdbfff7e71
https://dspace.library.uu.nl/handle/1874/409992
https://dspace.library.uu.nl/handle/1874/409992
Autor:
Crutzen, Stijn, Baas, Gert, Abou, Jamila, van den Born-Bondt, Tessa, Hugtenburg, Jacqueline G., Bouvy, Marcel L., Heringa, Mette, Taxis, Katja, Denig, Petra, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Frontiers in Pharmacology, 11:1268. Frontiers Media S.A.
Frontiers in Pharmacology, 11. Frontiers Media S.A.
Crutzen, S, Baas, G, Abou, J, van den Born-Bondt, T, Hugtenburg, J G, Bouvy, M L, Heringa, M, Taxis, K & Denig, P 2020, ' Barriers and Enablers of Older Patients to Deprescribing of Cardiometabolic Medication: A Focus Group Study ', Frontiers in Pharmacology, vol. 11, 1268 . https://doi.org/10.3389/fphar.2020.01268
Frontiers in Pharmacology, Vol 11 (2020)
Frontiers in Pharmacology
Frontiers in Pharmacology, 11:1268. Frontiers Media SA
Frontiers in Pharmacology, 11. Frontiers Media S.A.
Crutzen, S, Baas, G, Abou, J, van den Born-Bondt, T, Hugtenburg, J G, Bouvy, M L, Heringa, M, Taxis, K & Denig, P 2020, ' Barriers and Enablers of Older Patients to Deprescribing of Cardiometabolic Medication: A Focus Group Study ', Frontiers in Pharmacology, vol. 11, 1268 . https://doi.org/10.3389/fphar.2020.01268
Frontiers in Pharmacology, Vol 11 (2020)
Frontiers in Pharmacology
Frontiers in Pharmacology, 11:1268. Frontiers Media SA
Background Deprescribing has been recommended for managing polypharmacy but deprescribing preventive medication in older patients is still uncommon. We aimed to investigate older patients' barriers to and enablers of deprescribing cardiometabolic med
Autor:
Vreman, Rick A., Naci, Huseyin, Goettsch, Wim G., Mantel-Teeuwisse, Aukje K., Schneeweiss, Sebastian G., Leufkens, Hubert G.M., Kesselheim, Aaron S., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Clinical Pharmacology and Therapeutics, 108(2), 350. Nature Publishing Group
Clinical Pharmacology and Therapeutics
Clinical Pharmacology and Therapeutics
Assessments of clinical evidence vary between regulators and health technology assessment bodies, but precise differences remain unclear. To compare uncertainties raised on the clinical evidence of approved drugs, we analyzed assessments of regulator
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e0959d8e7732568b39ed85e54a6beac
http://eprints.lse.ac.uk/104271/
http://eprints.lse.ac.uk/104271/
Autor:
van Berlo – van de Laar, I. R.F., Brummelhuis, W. J., Imholz, A. L.T., Schellens, J. H., Huitema, A. D.R., Jansman, F. G.A., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Journal of Clinical Pharmacy and Therapeutics, 43(4), 574. Blackwell Publishing Ltd
Journal of Clinical Pharmacy and Therapeutics, 43(4), 574. Wiley-Blackwell
Journal of Clinical Pharmacy and Therapeutics, 43(4), 574-577. Blackwell Publishing Ltd
Journal of Clinical Pharmacy and Therapeutics, 43(4), 574. Wiley-Blackwell
Journal of Clinical Pharmacy and Therapeutics, 43(4), 574-577. Blackwell Publishing Ltd
WHAT IS KNOWN AND OBJECTIVE: Oxaliplatin in combination with fluorouracil and folinic acid is one of the preferred chemotherapeutic options in the treatment of metastatic rectum cancer. However, oxaliplatin is contraindicated in patients with a creat
Autor:
van Andel, Lotte, Zhang, Z, Lu, S., Kansra, V, Agarwal, S., Hughes, L., Tibben, M., Gebretensae, A., Lucas, L., Hillebrand, Michel J X, Rosing, H., Schellens, J H M, Beijnen, J H, Sub Inorganic Chemistry and Catalysis, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Investigational New Drugs
Investigational New Drugs, 35(6), 751. Kluwer Academic Publishers
Investigational New Drugs, 35(6), 751. Kluwer Academic Publishers
SummaryNiraparib is an investigational oral, once daily, selective poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor. In the pivotal Phase 3 NOVA/ENGOT/OV16 study, niraparib met its primary endpoint of improving progression-free survival (PFS
Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment
Autor:
Rolfo, Christian, de Vos-Geelen, Judith, Isambert, Nicolas, Molife, L Rhoda, Schellens, Jan H M, De Grève, Jacques, Dirix, Luc, Grundtvig-Sørensen, Peter, Jerusalem, Guy, Leunen, Karin, Mau-Sørensen, Morten, Plummer, Ruth, Learoyd, Maria, Bannister, Wendy, Fielding, Anitra, Ravaud, Alain, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Clinical Pharmacokinetics, 58(9), 1165-1174. Adis International Ltd
Clinical Pharmacokinetics, 58(9), 1165. Adis International Ltd
Clinical Pharmacokinetics, 58(9), 1165. Adis International Ltd
BACKGROUND: Olaparib, a potent oral poly(ADP-ribose) polymerase inhibitor, is partially renally cleared. We investigated the pharmacokinetics and safety of olaparib in patients with mild or moderate renal impairment to provide dosing recommendations.
Autor:
Vreman, Rick A, Bouvy, Jacoline C, Bloem, Lourens T, Hövels, Anke M, Mantel-Teeuwisse, Aukje K, Leufkens, Hubert G M, Goettsch, Wim G, Afd Pharmacoepi & Clinical Pharmacology, Sub Pharmacoepidemiology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Clinical Pharmacology and Therapeutics, 105(3), 684. Nature Publishing Group
This study assessed whether five Health Technology Assessment (HTA) bodies in Europe were more negative about drugs with a Conditional Marketing Authorization (CMA) that are approved without controlled studies compared to CMA drugs that are approved
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bdcd090bc826ada998f0d216f58bd6f
https://dspace.library.uu.nl/handle/1874/390145
https://dspace.library.uu.nl/handle/1874/390145